The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Potent antibody drug conjugates for cancer therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,382
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0789 · Cited by 1,247
Self-citationDevelopment of potent monoclonal antibody auristatin conjugates for cancer therapy
Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt832 · Cited by 1,206
Self-citationArming antibodies: prospects and challenges for immunoconjugates
Wu, A. M., & Senter, P. D. (2005) · Nature Biotechnology · doi:10.1038/nbt1141 · Cited by 1,052
Self-citationFrancisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejniak, S. X., Gordon, K. A., DeBlanc, R., Toki, B. E., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0039 · Cited by 931
Self-citationApproval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855
Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
Chari, R. V. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700108g · Cited by 815
Monoclonal antibody successes in the clinic
Reichert, J. M., Rosensweig, C. J., Faden, L. B., & Dewitz, M. C. (2005) · Nature Biotechnology · doi:10.1038/nbt0905-1073 · Cited by 733
Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.-R., Upeslacis, J., Shochat, D., et al. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010021y · Cited by 594
Erickson, H. K., Park, P. U., Widdison, W. C., Kovtun, Y. V., Garrett, L. M., Hoffman, K., Lutz, R. J., Goldmacher, V. S., & Blättler, W. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4489 · Cited by 584
Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates
Trail, P. A., Willner, D., Lasch, S. J., Henderson, A. J., Hofstead, S., Casazza, A. M., Firestone, R. A., Hellström, I., & Hellström, K. E. (1993) · Science · doi:10.1126/science.8327892 · Cited by 556
Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., Zabinski, R. F., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc0502917 · Cited by 515
Self-citationContribution of Linker Stability to the Activities of Anticancer Immunoconjugates
Alley, S. C., Benjamin, D. R., Jeffrey, S. C., Okeley, N. M., Meyer, D. L., Sanderson, R. J., & Senter, P. D. (2008) · Bioconjugate Chemistry · doi:10.1021/bc7004329 · Cited by 479
Self-citationKovtun, Y. V., Audette, C. A., Ye, Y., Xie, H., Ruberti, M. F., Phinney, S. J., Leece, B. A., Chittenden, T., Blättler, W. A., & Goldmacher, V. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3973 · Cited by 479
Larson, R. A., Sievers, E. L., Stadtmauer, E. A., Löwenberg, B., Estey, E. H., Dombret, H., Theobald, M., Voliotis, D., Bennett, J. M., Richie, M., et al. (2005) · Cancer · doi:10.1002/cncr.21326 · Cited by 460
Development trends for monoclonal antibody cancer therapeutics
Reichert, J. M., & Valge-Archer, V. E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2241 · Cited by 389
Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides
Sun, M. M. C., Beam, K. S., Cerveny, C. G., Hamblett, K. J., Blackmore, R. S., Torgov, M. Y., Handley, F. G. M., Ihle, N. C., Senter, P. D., & Alley, S. C. (2005) · Bioconjugate Chemistry · doi:10.1021/bc050201y · Cited by 370
Self-citationDiJoseph, J. F., Armellino, D. C., Boghaert, E. R., Khandke, K., Dougher, M. M., Sridharan, L., Kunz, A., Hamann, P. R., Gorovits, B., Udata, C., et al. (2004) · Blood · doi:10.1182/blood-2003-07-2466 · Cited by 361
Semisynthetic Maytansine Analogues for the Targeted Treatment of Cancer
Widdison, W. C., Wilhelm, S. D., Cavanagh, E. E., Whiteman, K. R., Leece, B. A., Kovtun, Y., Goldmacher, V. S., Xie, H., Steeves, R. M., Lutz, R. J., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060319f · Cited by 309
In vivo Drug-Linker Stability of an Anti-CD30 Dipeptide-Linked Auristatin Immunoconjugate
Sanderson, R. J., Hering, M. A., James, S. F., Sun, M. M. C., Doronina, S. O., Siadak, A. W., Senter, P. D., & Wahl, A. F. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.843.11.2 · Cited by 285
Self-citationRandomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer
Tolcher, A. W., Sugarman, S., Gelmon, K. A., Cohen, R., Saleh, M., Isaacs, C., Young, L., Healey, D., Onetto, N., & Slichenmyer, W. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.478 · Cited by 271
Polson, A. G., Calemine-Fenaux, J., Chan, P., Chang, W., Christensen, E., Clark, S., de Sauvage, F. J., Eaton, D., Elkins, K., Elliott, J. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2250 · Cited by 252
Cell killing by antibody–drug conjugates
Kovtun, Y. V., & Goldmacher, V. S. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.04.010 · Cited by 246
Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment
McDonagh, C. F., Turcott, E., Westendorf, L., Webster, J. B., Alley, S. C., Kim, K., Andreyka, J., Stone, I., Hamblett, K. J., Francisco, J. A., et al. (2006) · Protein Engineering Design and Selection · doi:10.1093/protein/gzl013 · Cited by 243
Thorpe, P. E., Wallace, P. M., Knowles, P. P., Relf, M., Brown, A. N. F., Watson, G., Knyba, R. E., Wawrzynczak, E. J., & Blakey, D. C. (1987) · PubMed · Cited by 204
Saleh, M. N., Sugarman, S., Murray, J., Ostroff, J. B., Healey, D., Jones, D., Daniel, C. R., LeBherz, D., Brewer, H., Onetto, N., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2282 · Cited by 196
Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.
Liu, C., Tadayoni, B. M., Bourret, L. A., Mattocks, K. M., Derr, S. M., Widdison, W. C., Kedersha, N. L., Ariniello, P. D., Goldmacher, V. S., Lambert, J. M., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8618 · Cited by 196
Dubowchik, G. M., & Firestone, R. A. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00609-x · Cited by 188
CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.
Tse, K. F., Jeffers, M., Pollack, V. A., McCabe, D. A., Shadish, M. L., Khramtsov, N. V., Hackett, C. S., Shenoy, S. G., Kuang, B., Boldog, F. L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2018 · Cited by 183
Self-citationLaw, C., Gordon, K. A., Toki, B. E., Yamane, A. K., Hering, M. A., Cerveny, C. G., Petroziello, J. M., Ryan, M. C., Smith, L. M., Simon, R., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2883 · Cited by 160
Self-citationHenry, M. D., Wen, S., Silva, M. D., Chandra, S., Milton, M., & Worland, P. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1722 · Cited by 156
Antibody-targeted chemotherapy with immunoconjugates of calicheamicin
Damle, N. K. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(03)00083-3 · Cited by 155
Thorpe, P. E., Wallace, P. M., Knowles, P. P., Relf, M., Brown, A. N., Watson, G., Blakey, D. C., & Newell, D. R. (1988) · PubMed · Cited by 155
Tassone, P., Gozzini, A., Goldmacher, V. S., Shammas, M. A., Whiteman, K. R., Carrasco, D. R., Li, C., Allam, C. K., Venuta, S., Anderson, K. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0142 · Cited by 152
Monoclonal antibody drug immunoconjugates for targeted treatment of cancer
Trail, P. A., King, D. H., & Dubowchik, G. M. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-002-0352-9 · Cited by 140
Ma, D., Hopf, C. E., Malewicz, A. D., Donovan, G. P., Senter, P. D., Goeckeler, W. F., Maddon, P. J., & Olson, W. C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2107 · Cited by 139
Self-citationKing, D., Dubowchik, G. M., Mastalerz, H. A., Willner, D., Hofstead, S. J., Firestone, R. A., Lasch, S. J., & Trail, P. A. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020149g · Cited by 135
DiJoseph, J. F., Dougher, M. M., Armellino, D. C., Evans, D. Y., & Damle, N. K. (2007) · Leukemia · doi:10.1038/sj.leu.2404866 · Cited by 134
EphB2 as a Therapeutic Antibody Drug Target for the Treatment of Colorectal Cancer
Mao, W., Luis, E., Ross, S., Silva, J., Tan, C., Crowley, C. W., Chui, C. H., Franz, G., Senter, P. D., Koeppen, H., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1047 · Cited by 127
Self-citationTassone, P., Goldmacher, V. S., Neri, P., Gozzini, A., Shammas, M. A., Whiteman, K. R., Hylander-Gans, L., Carrasco, D. R., Hideshima, T., Shringarpure, R., et al. (2004) · Blood · doi:10.1182/blood-2004-03-0963 · Cited by 124
Efficient Elimination of B-Lineage Lymphomas by Anti-CD20–Auristatin Conjugates
Law, C., Cerveny, C. G., Gordon, K. A., Klussman, K., Mixan, B. J., Chace, D. F., Meyer, D. L., Doronina, S. O., Siegall, C. B., Francisco, J. A., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1028 · Cited by 116
Self-citationDiJoseph, J. F., Goad, M. E. P., Dougher, M. M., Boghaert, E. R., Kunz, A., Hamann, P. R., & Damle, N. K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1134 · Cited by 99
Chen, Y., Clark, S., Wong, T., Chen, Y., Chen, Y., Dennis, M. S., Luis, E., Zhong, F., Bheddah, S., Koeppen, H., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4512 · Cited by 94
Antibody targeting of B-cell maturation antigen on malignant plasma cells
Ryan, M. C., Hering, M. A., Peckham, D., McDonagh, C. F., Brown, L. L., Kim, K. M., Meyer, D. L., Zabinski, R. F., Grewal, I. S., & Carter, P. J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0464 · Cited by 89
Pollack, V. A., Álvarez, E., Tse, K. F., Torgov, M. Y., Xie, S., Shenoy, S. G., MacDougall, J. R., Arrol, S., Zhong, H., Gerwien, R. W., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0490-z · Cited by 82
Self-citationHamann, P. R., Hinman, L. M., Beyer, C. F., Greenberger, L. M., Lin, C. J., Lindh, D., Menendez, A. T., Wallace, R., Durr, F. E., & Upeslacis, J. (2005) · Bioconjugate Chemistry · doi:10.1021/bc049795f · Cited by 81
Afar, D., Bhaskar, V., Ibsen, E. M., Breinberg, D., Henshall, S. M., Kench, J. G., Drobnjak, M., Powers, R., Wong, M. H. L., Evangelista, F., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.921.3.8 · Cited by 81
Hollander, I. J., Kunz, A., & Hamann, P. R. (2007) · Bioconjugate Chemistry · doi:10.1021/bc700321z · Cited by 80
Sievers, E. L. (2001) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.1.5.893 · Cited by 78
Boghaert, E. R., Sridharan, L., Armellino, D. C., Khandke, K. M., DiJoseph, J. F., Kunz, A., Dougher, M. M., Jiang, F., Kalyandrug, L. B., Hamann, P. R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0037 · Cited by 75
Boghaert, E. R., Khandke, K. M., Sridharan, L., Dougher, M. M., DiJoseph, J. F., Kunz, A., Hamann, P. R., Moran, J. K., Chaudhary, I., & Damle, N. K. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0560-2 · Cited by 66
Tumour-targeted chemotherapy with immunoconjugates of calicheamicin
Damle, N. K. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.9.1445 · Cited by 66
Trail, P. A., Willner, D., Knipe, J. O., Henderson, A. J., Lasch, S. J., Zoeckler, M. E., TrailSmith, M. D., Doyle, T. W., King, D., Casazza, A. M., et al. (1997) · PubMed · Cited by 65
E-selectin up-regulation allows for targeted drug delivery in prostate cancer.
Bhaskar, V., Law, D. A., Ibsen, E. M., Breinberg, D., Cass, K. M., DuBridge, R. B., Evangelista, F., Henshall, S. M., Hevezi, P. A., Miller, J. C., et al. (2003) · PubMed · Cited by 65
Self-citationSynthesis of an immunoconjugate of camptothecin
Walker, M. A., Dubowchik, G. M., Hofstead, S. J., Trail, P. A., & Firestone, R. A. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00707-7 · Cited by 53
Beeram, M., Burris, H. A., Modi, S., Birkner, M., Girish, S., Tibbitts, J., Holden, S. N., Lutzker, S. G., & Krop, I. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.1028 · Cited by 48
Boghaert, E. R., Sridharan, L., Khandke, K. M., Armellino, D. C., Ryan, M., Myers, K. A., Harrop, R., Kunz, A., Hamann, P., Marquette, K., et al. (2008) · International Journal of Oncology · doi:10.3892/ijo.32.1.221 · Cited by 41
Chemoimmunoconjugates for the Treatment of Cancer
Pietersz, G. A., Rowland, A. J., Smyth, M. J., & McKenzie, I. F. C. (1994) · Advances in immunology · doi:10.1016/s0065-2776(08)60455-1 · Cited by 38
αv Integrin-Targeted Immunoconjugates Regress Established Human Tumors in Xenograft Models
Chen, Q., Millar, H. J., McCabe, F. L., Manning, C. D., Steeves, R. M., Lai, K., Kellogg, B. A., Lutz, R. J., Trikha, M., Nakada, M. T., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0026 · Cited by 35
Mita, M. M., Ricart, A. D., Mita, A. C., Patnaik, A., Sarantopoulos, J., Sankhala, K. K., Fram, R. J., Qin, A., Watermill, J., & Tolcher, A. W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3062 · Cited by 24
Cited by
Natural products: A continuing source of novel drug leads
Cragg, G. M., & Newman, D. J. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.02.008 · Cited by 2,906
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Cancer nanomedicine: A review of recent success in drug delivery
Tran, S., DeGiovanni, P., Piel, B., & Rai, P. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0175-0 · Cited by 879
Metadata
- Authors
- Senter, P. D.
- Venue
- Current Opinion in Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2009-06
- Volume
- 13
- Issue
- 3
- Pages
- 235-244
- ISSN
- 1367-5931 (ISSN-L)
- OpenAlex
- W1990918503
- Cited by
- 401
- References
- 60
- FWCI
- 4.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.